AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35474627
Drug: Inpatient multimodal
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient multimodal treatment (IMT)
Trial: 33865471
Drug: 3-monthly ART
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-monthly ART dispensing
Trial: 33865471
Drug: 6-monthly ART
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6-monthly ART dispensing
Trial: 34334898
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg twice on day 1, then 400 mg once daily from day 2 to day 5
Trial: 34372928
Drug: Nutricia™ preOp®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutricia™ preOp® (400 mL) administered to the pre-op group after 10 hours of fasting.
Trial: 34936159
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both methods (TC-APP)
Trial: 32618267
Drug: Dihydroartemisinin-piperaquine (DHAp)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DHAp) administered during MDA/fMDA
Trial: 35120577
Drug: High single
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High single dose of vitamin D (140,000 IU) followed by treatment as usual (TAU)
Trial: 35120577
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + treatment as usual (TAU)
Trial: 33828219
Drug: Exploratory cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploratory cohort patients measuring upper vertical lung length (uVLL), lower vertical lung length (lVLL), total vertical lung length (tVLL), and l/uVLL ratio on chest X-rays.
Trial: 33828219
Drug: l/uVLL ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l/uVLL ratio measurement
Trial: 33899607
Drug: Commonly used
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commonly used generalized linear models (e.g., logistic regression, Poisson regression)
Trial: 34909972
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone 40 mg/day
Trial: 34909972
Drug: Micronized vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized vaginal progesterone 800 mg/day
Trial: 33399242
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy without chemotherapy
Trial: 36859316
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution (control)
Trial: 35475947
Drug: 6 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 sessions of treatment
Trial: 35475947
Drug: 12 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 sessions of treatment
Trial: 33309893
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution (placebo)
Trial: 32412157
Drug: Nivolumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment <2 years
Trial: 32412157
Drug: Nivolumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment for 2 years
Trial: 32412157
Drug: Nivolumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment >2 years
Trial: 32412157
Drug: Nivolumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment (all groups)
Trial: 33974972
Drug: Standard intraprocedural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intraprocedural local anesthetic, intra‐arterial lidocaine, and intravenous analgesia (Control)
Trial: 32522320
Drug: Modified atraumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified atraumatic restorative treatment (mART)
Trial: 35987550
Drug: Compound intervention
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound intervention (IP + WBE), n=87
Trial: 32208168
Drug: INO-5150 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-5150 (2 mg)
Trial: 32208168
Drug: INO-5150 (8.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-5150 (8.5 mg)
Trial: 32208168
Drug: INO-5150 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-5150 (2 mg) + INO-9012 (1 mg)
Trial: 32208168
Drug: INO-5150 (8.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-5150 (8.5 mg) + INO-9012 (1 mg)
Trial: 36349571
Drug: PEEP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEP titration to the lowest driving pressure
Trial: 32591439
Drug: Intensive hypertension
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive hypertension treatment (targeting systolic BP <120 mm Hg)
Trial: 32591439
Drug: Standard hypertension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hypertension treatment (targeting systolic BP <140 mm Hg)
Trial: 32591439
Drug: Incident eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incident eGFR <60 ml/min per 1.73 m2
Trial: 32591439
Drug: Baseline and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline and incident urinary ACR ≥30 mg/g
Trial: 34657407
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of cardiovascular drugs (aspirin, antihypertensives, statins)
Trial: 32448722
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch supplementation (35 g/d)
Trial: 35921606
Drug: New cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cancer drugs
Trial: 34393120
Drug: 2.5% lidocaine/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% lidocaine/2.5% prilocaine topical anesthetic
Trial: 34393120
Drug: Injection anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection anesthetic
Trial: 34393120
Drug: L/P topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/P topical anesthetic
Trial: 35466800
Drug: Counselling program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling program based on cognitive behavioural therapy (16 sessions)
Trial: 32213303
Drug: Plasma suPAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma suPAR level above 3.70 ng mL-1
Trial: 34643947
Drug: Histology-tailored (HT)
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histology-tailored (HT) chemotherapy
Trial: 33094898
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and passive muscle stretching exercises
Trial: 33017854
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (GPT)
Trial: 33264200
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) group (n = 30)
Trial: 33823924
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 0.375% ropivacaine 0.4 ml/kg
Trial: 33823924
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block (TPVB) with 0.375% ropivacaine 0.4 ml/kg
Trial: 35817286
Drug: Methylprednisolone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (60 mg/day in two divided doses)
Trial: 32272777
Drug: LF-containing yogurt
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF-containing yogurt (100 mg/day)
Trial: 33876660
Drug: Song of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Song of Life music therapy intervention
Trial: 34225757
Drug: First trimester
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First trimester PM2.5 concentration increase (20.1 µg/m3)
Trial: 33136069
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics after UTI
Trial: 35924869
Drug: MedMon (medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedMon (medication monitoring control)
Trial: 32725244
Drug: Stepwise approach
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepwise approach including 6-month lifestyle modification curriculum plus metformin
Trial: 36501086
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric Carboxymaltose (FCM) 500 mg IV infusion, given at time 0 and repeated after 4 weeks
Trial: 36501086
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mL of saline given i.v. in 10 min), n = 32
Trial: 34836336
Drug: Cooked coix
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooked coix seed (160 g per day) for 7 days
Trial: 33966521
Drug: Diuretic adjustment
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic adjustment algorithm (DAA) with telephone follow-ups for 30 days
Trial: 33966521
Drug: Diuretic adjustment
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic adjustment algorithm (DAA)
Trial: 33966521
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - diuretic dose adjusted by physician at baseline only
Trial: 32846573
Drug: Mango juice
RxNorm normalized name: mango juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mango juice by-product (JBP) beverage (0.04 g·ml-1)
Trial: 34674670
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen 10 mg/kg
Trial: 32173020
Drug: Canal preparation
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canal preparation using Protaper Next files until size X3
Trial: 32173020
Drug: Canal preparation
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canal preparation using Protaper Next files until size X5
Trial: 34073610
Drug: 500 g
RxNorm normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g daily of bitter and strong-tasting (BST) vegetables
Trial: 34073610
Drug: 500 g
RxNorm normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g daily of mild and sweet-tasting (MST) vegetables
Trial: 34073610
Drug: 120 g
RxNorm normalized name: soap 120 gram TOPICAL BAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 g daily MST normal diet (control)
Trial: 36113110
Drug: Nonsupervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsupervised physical activity (30 min of self-administered physical aerobic activity daily for 2 weeks before and 4 weeks after surgery)
Trial: 36113110
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy subgroup
Trial: 32314505
Drug: 2.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg/kg GLP-1-gFc
Trial: 32314505
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg dulaglutide
Trial: 32314505
Drug: 0.28 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.28 mg/kg GLP-1-gFc
Trial: 32314505
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg dulaglutide
Trial: 32648641
Drug: Peanut protein
RxNorm normalized name: peanut protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut protein ingestion (300-1000 mg)
Trial: 32404169
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera 3% topical ointment
Trial: 35569763
Drug: 1-mg intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mg intravitreal risuteganib injection
Trial: 32708396
Drug: exercise routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO)
Trial: 35124144
Drug: Ethanol-based (WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol-based (WHO gel formulation)
Trial: 35124144
Drug: Ethanol-based with
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol-based with superfatting agents (Saniswiss Sanitizer Hands H1)
Trial: 35177467
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (relevant lifestyle advice and cardio‐preventive medication)
Trial: 32521284
Drug: Vibration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration therapy (10 self-applied sessions)
Trial: 34960106
Drug: Liposomal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal formulation of vitamin A
Trial: 32481287
Drug: Dan-Hong Hua-Yu
RxNorm normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dan-Hong Hua-Yu oral solution
Trial: 35466808
Drug: Standard hydrocolloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hydrocolloid gel dressings (HG)
Trial: 35238798
Drug: HIIE +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIE + MLT (3 mg)
Trial: 34688568
Drug: Corticision-assisted orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticision-assisted orthodontic treatment (CORT); n=26 (6 males, 20 females, mean age 21.30)
Trial: 34688568
Drug: Traditional orthodontic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional orthodontic treatment (TRAD); n=26 (8 males, 18 females, mean age 21.46)
Trial: 34688568
Drug: Corticision-assisted orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticision-assisted orthodontic treatment (CORT)
Trial: 34688568
Drug: Traditional orthodontic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional orthodontic treatment (TRAD)
Trial: 34364917
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT)
Trial: 34364917
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 μg/kg daily for the first 5 days and every third day thereafter until day 26) plus SMT
Trial: 33444874
Drug: Fluency shaping
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluency shaping treatment (soft voice onsets)
Trial: 32736893
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day for 7 days
Trial: 32736893
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day for 7 days
Trial: 32620144
Drug: Ultra-short-wave diathermy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-short-wave diathermy treatment + nationally recommended standard medical treatment
Trial: 32620144
Drug: Nationally recommended
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nationally recommended standard medical treatment
Trial: 35662337
Drug: Mezlocillin 50
RxNorm normalized name: Mezlocilline
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mezlocillin 50 mg/kg q12h
Trial: 35662337
Drug: Mezlocillin 20
RxNorm normalized name: mezlocillin 20 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin 20 mg/kg q8h
Trial: 36462182
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (high-dose vitamin D3)
Trial: 36462182
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (high-dose vitamin D3) in those taking antidepressants at baseline
Trial: 36462182
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (high-dose vitamin D3) in participants with predicted 25(OH)D concentration <50 nmol/L
Trial: 36462182
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (high-dose vitamin D3) in participants with predicted 25(OH)D ≥50 nmol/L
Trial: 32900220
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment (cognitive behavioural treatment and motivational enhancement)
Trial: 32900220
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (alcohol-focused treatment)
Trial: 32900220
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Integrated and Control)
Trial: 33725772
Drug: Antiviral medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiviral medications
Trial: 35788739
Drug: Inhaled ginger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ginger essential oil
Trial: 35788739
Drug: Inhaled German
RxNorm normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled German chamomile essential oil
Trial: 35788739
Drug: Inhaled bergamot
RxNorm normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bergamot essential oil
Trial: 35638561
Drug: CJM112 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJM112 300 mg (anti-IL-17A IgG1/κ monoclonal antibody)
Trial: 36467553
Drug: Zaoren Anshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaoren Anshen capsule and 5 mg zolpidem tartrate (Group ZA + Z5)
Trial: 36467553
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zolpidem tartrate (Group Z10)
Trial: 36467553
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zolpidem tartrate and placebo capsule (Group Z5)
Trial: 36467553
Drug: Zaoren Anshen
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaoren Anshen capsule and placebo pill (Group ZA)
Trial: 34052844
Drug: Probiotic compounds
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic compounds (4 strains; Lactobacillus plantarum MH‐301, L. rhamnosus LGG‐18, L. acidophilus, Bifidobacterium animalis subsp.lactis LPL‐RH)
Trial: 34052844
Drug: Probiotic compounds
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic compounds administration in rat models
Trial: 32386395
Drug: THC (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (7.5 and/or 15 mg oral)
Trial: 35460517
Drug: Self-management intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management intervention for lung cancer surgery preparation/recovery
Trial: 33038967
Drug: Subcutaneous vosoritide
RxNorm normalized name: vosoritide
DrugBank: Vosoritide (DB11928)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous vosoritide therapy
Trial: 33864354
Drug: Magnesium +
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium + Vitamin B6 (Magne B6®; daily dose 300 mg magnesium and 30 mg vitamin B6)
Trial: 33864354
Drug: Magnesium alone
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium alone (Magnespasmyl®; daily dose 300 mg)
Trial: 32372561
Drug: Local methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local methylcobalamin injection and lidocaine (LM group)
Trial: 32372561
Drug: Intramuscular methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular methylcobalamin and local lidocaine (IM group)
Trial: 32372561
Drug: Oral methylcobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylcobalamin tablet and lidocaine local injection (OM group)